Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy

E. C C Wong, V. E. Maher, K. Hines, J. Lee, C. S. Carter, T. Goletz, W. Kopp, C. L. Mackall, J. A. Berzofsky, E. J. Read

Research output: Contribution to journalArticle

Abstract

Background: There is growing interest in the use of dendritic cells (DCs) for treatment of malignancy and infectious disease. Our goal was to develop a clinical-scale method to prepare autologous DCs for cancer clinical trials. Methods: PBMC were collected from normal donors or cancer patients by automated leukapheresis, purified by counterflow centrifugal elutriation and placed into culture in polystyrene flasks at 1 × 106 cells/mL for 5-7 days at 37°C, with 5% CO2, with IL-4 and GM-CSF. Conditions investigated included media formulation, supplementation with heat-inactivated allogeneic AB serum or autologous plasma and time to harvest (Day 5 or Day 7). DCs were evaluated for morphology, quantitative yield, viability, phenotype and function, including mixed leukocyte response and recall response to tetanus toxoid and influenza virus. Results: DCs with a typical immature phenotype (CD14-negative, CD1a-positive, mannose receptor-positive, CD80-positive, CD83-negative) were generated most consistently in RPMI 1640 supplemented with 10% allogeneic AB serum or 10% autologous plasma. Cell yield was higher at Day 5 than Day 7, without detectable differences in phenotype or function. In pediatric sarcoma patients, autologous DCs had enhanced function compared with monocytes from which they were generated. In this patient group, starting with 8.0± 3.7× 108 fresh or cryopreserved autologous monocytes, DC yield was 2.1±1.0 × 108 cells, or 29% of the starting monocyte number. Discussion: In the optimized clinical-scale method, purified peripheral monocytes are cultured for 5 days in flasks at 1 × 106 cells/mL in RPMI 1640, 10% allogeneic AB serum or autologous plasma, IL-4 and GM-CSF. This method avoids the use of FBS and results in immature DCs suitable for clinical trials.

Original languageEnglish (US)
Pages (from-to)19-29
Number of pages11
JournalCytotherapy
Volume3
Issue number1
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Immunotherapy
Dendritic Cells
Monocytes
Neoplasms
Granulocyte-Macrophage Colony-Stimulating Factor
Phenotype
Interleukin-4
Serum
Clinical Trials
Leukapheresis
Tetanus Toxoid
Polystyrenes
Orthomyxoviridae
Sarcoma
Communicable Diseases
Leukocytes
Hot Temperature
Tissue Donors
Pediatrics

Keywords

  • Dendritic cells (DCs)
  • Immunotherapy
  • Peripheral blood monocytes

ASJC Scopus subject areas

  • Immunology

Cite this

Wong, E. C. C., Maher, V. E., Hines, K., Lee, J., Carter, C. S., Goletz, T., ... Read, E. J. (2001). Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy. Cytotherapy, 3(1), 19-29. https://doi.org/10.1080/146532401753156377

Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy. / Wong, E. C C; Maher, V. E.; Hines, K.; Lee, J.; Carter, C. S.; Goletz, T.; Kopp, W.; Mackall, C. L.; Berzofsky, J. A.; Read, E. J.

In: Cytotherapy, Vol. 3, No. 1, 2001, p. 19-29.

Research output: Contribution to journalArticle

Wong, ECC, Maher, VE, Hines, K, Lee, J, Carter, CS, Goletz, T, Kopp, W, Mackall, CL, Berzofsky, JA & Read, EJ 2001, 'Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy', Cytotherapy, vol. 3, no. 1, pp. 19-29. https://doi.org/10.1080/146532401753156377
Wong, E. C C ; Maher, V. E. ; Hines, K. ; Lee, J. ; Carter, C. S. ; Goletz, T. ; Kopp, W. ; Mackall, C. L. ; Berzofsky, J. A. ; Read, E. J. / Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy. In: Cytotherapy. 2001 ; Vol. 3, No. 1. pp. 19-29.
@article{4f2a1f8672ed46feaa4a405be9633d40,
title = "Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy",
abstract = "Background: There is growing interest in the use of dendritic cells (DCs) for treatment of malignancy and infectious disease. Our goal was to develop a clinical-scale method to prepare autologous DCs for cancer clinical trials. Methods: PBMC were collected from normal donors or cancer patients by automated leukapheresis, purified by counterflow centrifugal elutriation and placed into culture in polystyrene flasks at 1 × 106 cells/mL for 5-7 days at 37°C, with 5{\%} CO2, with IL-4 and GM-CSF. Conditions investigated included media formulation, supplementation with heat-inactivated allogeneic AB serum or autologous plasma and time to harvest (Day 5 or Day 7). DCs were evaluated for morphology, quantitative yield, viability, phenotype and function, including mixed leukocyte response and recall response to tetanus toxoid and influenza virus. Results: DCs with a typical immature phenotype (CD14-negative, CD1a-positive, mannose receptor-positive, CD80-positive, CD83-negative) were generated most consistently in RPMI 1640 supplemented with 10{\%} allogeneic AB serum or 10{\%} autologous plasma. Cell yield was higher at Day 5 than Day 7, without detectable differences in phenotype or function. In pediatric sarcoma patients, autologous DCs had enhanced function compared with monocytes from which they were generated. In this patient group, starting with 8.0± 3.7× 108 fresh or cryopreserved autologous monocytes, DC yield was 2.1±1.0 × 108 cells, or 29{\%} of the starting monocyte number. Discussion: In the optimized clinical-scale method, purified peripheral monocytes are cultured for 5 days in flasks at 1 × 106 cells/mL in RPMI 1640, 10{\%} allogeneic AB serum or autologous plasma, IL-4 and GM-CSF. This method avoids the use of FBS and results in immature DCs suitable for clinical trials.",
keywords = "Dendritic cells (DCs), Immunotherapy, Peripheral blood monocytes",
author = "Wong, {E. C C} and Maher, {V. E.} and K. Hines and J. Lee and Carter, {C. S.} and T. Goletz and W. Kopp and Mackall, {C. L.} and Berzofsky, {J. A.} and Read, {E. J.}",
year = "2001",
doi = "10.1080/146532401753156377",
language = "English (US)",
volume = "3",
pages = "19--29",
journal = "Cytotherapy",
issn = "1465-3249",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy

AU - Wong, E. C C

AU - Maher, V. E.

AU - Hines, K.

AU - Lee, J.

AU - Carter, C. S.

AU - Goletz, T.

AU - Kopp, W.

AU - Mackall, C. L.

AU - Berzofsky, J. A.

AU - Read, E. J.

PY - 2001

Y1 - 2001

N2 - Background: There is growing interest in the use of dendritic cells (DCs) for treatment of malignancy and infectious disease. Our goal was to develop a clinical-scale method to prepare autologous DCs for cancer clinical trials. Methods: PBMC were collected from normal donors or cancer patients by automated leukapheresis, purified by counterflow centrifugal elutriation and placed into culture in polystyrene flasks at 1 × 106 cells/mL for 5-7 days at 37°C, with 5% CO2, with IL-4 and GM-CSF. Conditions investigated included media formulation, supplementation with heat-inactivated allogeneic AB serum or autologous plasma and time to harvest (Day 5 or Day 7). DCs were evaluated for morphology, quantitative yield, viability, phenotype and function, including mixed leukocyte response and recall response to tetanus toxoid and influenza virus. Results: DCs with a typical immature phenotype (CD14-negative, CD1a-positive, mannose receptor-positive, CD80-positive, CD83-negative) were generated most consistently in RPMI 1640 supplemented with 10% allogeneic AB serum or 10% autologous plasma. Cell yield was higher at Day 5 than Day 7, without detectable differences in phenotype or function. In pediatric sarcoma patients, autologous DCs had enhanced function compared with monocytes from which they were generated. In this patient group, starting with 8.0± 3.7× 108 fresh or cryopreserved autologous monocytes, DC yield was 2.1±1.0 × 108 cells, or 29% of the starting monocyte number. Discussion: In the optimized clinical-scale method, purified peripheral monocytes are cultured for 5 days in flasks at 1 × 106 cells/mL in RPMI 1640, 10% allogeneic AB serum or autologous plasma, IL-4 and GM-CSF. This method avoids the use of FBS and results in immature DCs suitable for clinical trials.

AB - Background: There is growing interest in the use of dendritic cells (DCs) for treatment of malignancy and infectious disease. Our goal was to develop a clinical-scale method to prepare autologous DCs for cancer clinical trials. Methods: PBMC were collected from normal donors or cancer patients by automated leukapheresis, purified by counterflow centrifugal elutriation and placed into culture in polystyrene flasks at 1 × 106 cells/mL for 5-7 days at 37°C, with 5% CO2, with IL-4 and GM-CSF. Conditions investigated included media formulation, supplementation with heat-inactivated allogeneic AB serum or autologous plasma and time to harvest (Day 5 or Day 7). DCs were evaluated for morphology, quantitative yield, viability, phenotype and function, including mixed leukocyte response and recall response to tetanus toxoid and influenza virus. Results: DCs with a typical immature phenotype (CD14-negative, CD1a-positive, mannose receptor-positive, CD80-positive, CD83-negative) were generated most consistently in RPMI 1640 supplemented with 10% allogeneic AB serum or 10% autologous plasma. Cell yield was higher at Day 5 than Day 7, without detectable differences in phenotype or function. In pediatric sarcoma patients, autologous DCs had enhanced function compared with monocytes from which they were generated. In this patient group, starting with 8.0± 3.7× 108 fresh or cryopreserved autologous monocytes, DC yield was 2.1±1.0 × 108 cells, or 29% of the starting monocyte number. Discussion: In the optimized clinical-scale method, purified peripheral monocytes are cultured for 5 days in flasks at 1 × 106 cells/mL in RPMI 1640, 10% allogeneic AB serum or autologous plasma, IL-4 and GM-CSF. This method avoids the use of FBS and results in immature DCs suitable for clinical trials.

KW - Dendritic cells (DCs)

KW - Immunotherapy

KW - Peripheral blood monocytes

UR - http://www.scopus.com/inward/record.url?scp=17744371122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17744371122&partnerID=8YFLogxK

U2 - 10.1080/146532401753156377

DO - 10.1080/146532401753156377

M3 - Article

VL - 3

SP - 19

EP - 29

JO - Cytotherapy

JF - Cytotherapy

SN - 1465-3249

IS - 1

ER -